The estimation of health state utility values in rare diseases: overview of existing techniques
暂无分享,去创建一个
[1] M. Drummond,et al. ‘Mapping’ Health State Utility Values from Non-preference-Based Measures: A Systematic Literature Review in Rare Diseases , 2020, PharmacoEconomics.
[2] D. Feeny,et al. Characterizing health state utilities associated with Duchenne muscular dystrophy: a systematic review , 2019, Quality of Life Research.
[3] P. Kanavos,et al. Health related quality of life aspects not captured by EQ-5D-5L: Results from an international survey of patients. , 2019, Health policy.
[4] L. Prosser,et al. Health utilities and parental quality of life effects for three rare conditions tested in newborns , 2019, Journal of Patient-Reported Outcomes.
[5] B. Arnould,et al. Illustration of patient-reported outcome challenges and solutions in rare diseases: a systematic review in Cushing’s syndrome , 2018, Orphanet Journal of Rare Diseases.
[6] A. Slade,et al. Patient reported outcome measures in rare diseases: a narrative review , 2018, Orphanet Journal of Rare Diseases.
[7] A. Olaye,et al. Economic Modeling Considerations for Rare Diseases. , 2018, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[8] J. Brazier,et al. Recommended Methods for the Collection of Health State Utility Value Evidence in Clinical Studies , 2017, PharmacoEconomics.
[9] John Brazier,et al. The Role of Condition-Specific Preference-Based Measures in Health Technology Assessment , 2017, PharmacoEconomics.
[10] J. Brazier,et al. A Review of Generic Preference-Based Measures for Use in Cost-Effectiveness Models , 2017, PharmacoEconomics.
[11] N. Weinstein,et al. Orphan Drugs In The Uk, Do They Meet The Nice Highly Specialised Technology Threshold? , 2017 .
[12] É. Silva,et al. Avaliação econômica no âmbito das doenças raras: isto é possível? , 2015 .
[13] Donna Rowen,et al. Mapping to obtain EQ-5D utility values for use in NICE health technology assessments. , 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[14] J. Brazier,et al. Using a discrete choice experiment to estimate health state utility values. , 2012, Journal of health economics.
[15] C. Lind,et al. Neurotrauma and the rule of rescue , 2011, Journal of Medical Ethics.
[16] J. Brazier,et al. NICE DSU Technical Support Document 11: Alternatives to EQ-5D for Generating Health State Utility Values [Internet] , 2011 .
[17] David T Arnold,et al. Comparison of direct and indirect methods of estimating health state utilities for resource allocation: review and empirical analysis , 2009, BMJ : British Medical Journal.
[18] R. Hays,et al. Reliability, validity, and minimally important differences of the SF-6D in systemic sclerosis , 2007, Quality of Life Research.
[19] D. Hughes,et al. Drugs for exceptionally rare diseases: do they deserve special status for funding? , 2005, QJM : monthly journal of the Association of Physicians.
[20] M. Wallace,et al. Assessment of Health State Utilities and Quality of Life in Patients With Malignant Esophageal Dysphagia , 2004, American Journal of Gastroenterology.
[21] P. Leigh,et al. Patients' health-related quality-of-life and health state values for motor neurone disease/amyotrophic lateral sclerosis , 2003, Quality of Life Research.
[22] Jeff Richardson,et al. The rule of rescue. , 2003, Social science & medicine.
[23] E. Nord. The Person-trade-off Approach to Valuing Health Care Programs , 1995, Medical decision making : an international journal of the Society for Medical Decision Making.